HER2-positive and triple-negative tumours generally achieve higher breast and nodal pCR rates under contemporary systemic regimens and may leave less small-volume residual nodal disease, whereas luminal tumours often retain microscopic metastases that are sonographically subtle and difficult to distinguish from reactive nodes [27,28,29,30,31]. The gene discussed is ERBB2; the disease is neoplasm.